HC Wainwright Cuts Valneva (NASDAQ:VALN) Price Target to $18.00

Valneva (NASDAQ:VALN) had its price target reduced by HC Wainwright from $19.00 to $18.00 in a report published on Thursday,Benzinga reports. They currently have a buy rating on the stock.

Valneva Stock Up 2.4 %

Shares of VALN opened at $4.74 on Thursday. The company’s 50 day simple moving average is $4.28 and its 200-day simple moving average is $5.80. Valneva has a 12-month low of $3.62 and a 12-month high of $9.50. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78.

Institutional Trading of Valneva

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC increased its position in shares of Valneva SE (NASDAQ:VALN) by 33.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 118,000 shares of the company’s stock after purchasing an additional 29,748 shares during the period. AlphaCentric Advisors LLC owned approximately 0.15% of Valneva worth $717,000 as of its most recent SEC filing. Institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.